DTech Liquidating

DTech Liquidating ROE

Delisted

The Return on Equity (ROE) of DTech Liquidating (DMTKQ) as of Nov 21, 2026 is -176.45 %. In the previous year, Return on Equity (ROE) was -88.13 % — a change of 100.23% (lower).

ROE

-176.45 %

YoY

100.23%

Last updated:

In 2023, DTech Liquidating's return on equity (ROE) was -176.45 %, a 100.23% increase from the -88.13 % ROE in the previous year.

The DTech Liquidating ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
-0.16 USD
Jan 1, 2018
12.54 USD
Jan 1, 2019
-157.52 USD
Jan 1, 2020
-57.45 USD
Jan 1, 2021
-34.11 USD
Jan 1, 2022
-88.13 USD
Jan 1, 2023
-176.45 USD
The DTech Liquidating ROE history
YEARROEYoY
-176.45 %+100.23%
-88.13 %+158.40%
-34.11 %-40.63%
-57.45 %-63.53%
-157.52 %-1,355.90%
12.54 %-7,832.65%
-0.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

ROE Details

Decoding DTech Liquidating's Return on Equity (ROE)

DTech Liquidating's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing DTech Liquidating's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

DTech Liquidating's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in DTech Liquidating’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about DTech Liquidating stock

Return on Equity (ROE) of DTech Liquidating is -176.45 % in 2023.

Return on Equity (ROE) of DTech Liquidating changed from -88.13 % to -176.45 %, representing a 100.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s DTech Liquidating with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — DTech Liquidating

All Key Metrics — DTech Liquidating